DEALS: AstraZeneca, BMS ink diabetes drug pact

DEALS

WHO

WITH

WHAT

SCOOP

AstraZeneca

Bristol-Myers Squibb

$1.05B deal

AZ has agreed to pay BMS $100M up front and up to $950M more in milestones to partner up on two new diabetes drugs, saxagliptin and dapagliflozin.

Genentech

Seattle Genetics

$860M development deal

The deal is for SGN-40, a early-stage cancer treatment being studied for multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

Eli Lilly

OSI

$385M licensing deal

OSI has licensed the exclusive rights to PSN010--its early-stage diabetes drug--to Eli Lilly for $25 million up front and up to $360 million in milestones plus royalty payments.

Genentech

BioInvent

$190M licensing deal

The deal is for BioInvent's BI-204, a preclinical therapy for reducing arterial plaque.

XTL Biopharmaceuticals

DOV Pharmaceutical

$134M licensing deal

XTL Biopharmaceuticals is licensing DOV Pharmaceuticals' rights to bicifadine as a treatment for neuropathic pain.

Biogen Idec

Syntonix Pharmaceuticals

$120M deal

Biogen gains a lead product for hemophilia B and technology for developing inhalable treatments.

Eli Lilly

Nicholas Piramal India

$100M development pact

Nicholas Piramal will advance some of Lilly's preclinical drug candidates in clinical trials in exchange for up to $100 million in milestones and a share of the royalties.

Health and Human Services

GlaxoSmithKline

$63.3M

GSK has won a $63.3 million contract from HHS to develop pre-pandemic and pandemic vaccines, supporting its research into adjuvants that boost the effectiveness of vaccines.

Pfizer

Genizon BioSciences

Licensing deal

Pfizer has licensed the diagnostic rights involved in the genetic research of Genizon BioSciences in Alzheimer's, ADHD, and endometriosis.

Wyeth Pharmaceuticals

Pharmacopeia

Development deal

Wyeth has inked a pact for Pharmacopeia's JAK3 inhibitor program, which focuses on the activation of T-cells for rheumatoid arthritis, psoriasis and other immunological conditions.

Wyeth Pharmceutical

Solvay

Development deal

Solvay and Wyeth Pharmceutical are expanding their existing neuroscience co-development and co-commercialization agreement to include research in neuroscience.

Pfizer

Archemix

Discovery pact

Archemix has agreed to employ its know-how in discovering aptamer-based drugs for Pfizer.